Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361 Meeting Abstract
| Authors: | Powles, T.; Alva, A. S.; Ozguroglu, M.; O'Donnell, P. H.; Loriot, Y.; Csoszi, T.; Vuky, J.; Morales-Barrera, R.; Plimack, E. R.; Matsubara, N.; Fradet, Y.; Geczi, L.; Gunduz, S.; Mamtani, R.; Bajorin, D. F.; Liu, C. C.; Imai, K.; Moreno, B. H.; Bellmunt, J.; Balar, A. V. |
| Abstract Title: | Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361 |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900526 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.519 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 519 -- Meeting was conducted online as well as in person -- Source: Wos |
